Utility-based evaluation of the quality of life of patient's with gastric cancer who receive chemotherapy: Comparison of patients' quality of life between oral TS-1 and conventional injectable combination therapy

Yakugaku Zasshi

Volumn 128, Issue 5, 2008, Pages 783-793

  Shimizu, Hisanori ^a   Tanaka, Katsumi ^a   Ikeda, Shunya ^b   Sakamaki, Hiroyuki ^c   Yajima, Shuichi ^d   Ikegami, Naoki ^d   Murayama, Jun Ichiro ^a  

^a SHOWA UNIVERSITY HOSPITAL   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Quality of life (QOL); TS 1 (tegafur, gimeracil, oteracil potassium); Utility

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; GIMERACIL; OTERACIL POTASSIUM; TEGAFUR;

ARTICLE; CANCER CHEMOTHERAPY; HEALTH SURVEY; HUMAN; QUALITY OF LIFE; STOMACH CANCER;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OXONIC ACID; QUALITY OF LIFE; QUESTIONNAIRES; STOMACH NEOPLASMS; TEGAFUR;

EID: 43449125950     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.783     Document Type: Article

References (37)

1. Ishikawa B. K., Jpn. J. Cancer Chemother., 33, 159-163 (2006).
2. Ikeda S., Prog. Med., 26, 1003-1007 (2006).
3. Hinotsu A., Akaza H., Jpn. J. Cancer Chemother., 27, 676-682 (2000).
4. Fumimoto H., Kobayashi K., Chang C. H., Eremenco S., Fujiki Y., Uemura S., Ohashi Y., Kudoh S., Qual. Life Res., 10, 701-709 (2001).
5. Yoshimura A., Kobayashi K., Fumimoto H., Fujiki Y., Eremenco S., Kudho S., J. Nippon Med. Sch., 71, 314-322 (2004).
6. Vickery C. W., Blazeby J. M., Conroy T., Arraras J., Sezer O., Koller M., Rosemeyer D., Johnson C. D., Alderson D., Eur. J. Cancer, 37, 966-971 (2001).
7. Mystakidou K., Tsilika E., Parpa E., Kalaidopoulou O., Smyrniotis V., Vlahos L., Int. J. Cancer, 94, 135-139 (2001).
8. Morita S., Shimozuma K., Sato A., Nakamachi M., Blazeby J., West K., Hukuhara S., Sakamoto J., Jpn. J. Cancer Chemother., 31, 1195-1199 (2004).
9. Kaptein A. A., Morita S., Sakamoto J., World J. Gastroenterol., 11, 3189-3196 (2005).
10. Shimozuma K., J. Inst. Public Health, 53, 198-203 (2004).
11. Eguchi K., Kurihara M., Shimozuma K., Horita T., Murakami M., Suzuki N., Ishikawa K., Ogawa H., Kobayashi K., Shimizu H., Tsuboi K., J. Jpn. Soc. Cancer Ther., 28, 1140-1144 (1993).
12. Nakamachi M., Sato A., Shimada K., Kurihara M., Matsukawa M., Rinsho Seijinnbyou, 31, 118-122 (2001).
13. Ikegami N., Hukuhara S., Shimozuma K., Ikeda S., "QOL Evaluatiuon Hund-book", Igakushoinn Co., Ltd., Tokyo, 2001, pp. 1-149.
14. Ikeda S., Ikegami N., Igakunoayumi, 213, 137-141 (2005).
15. Mutou M., Rinsho Seijinnbyou, 31, 118-122 (2001).
16. Morimoto T., Fukui T., J. Epidemiol., 12, 160-178 (2002).
17. Earle C. C., Chapman R. H., Baker C. S., J. Clin. Oncol., 18, 3302-3317 (2000).
18. Tanaka K., Kaetsu T., Suzuki S., Kusano M., Yajima S., Sakamaki H., Ikeda S., Ikegami N., Murayama J., Jpn. J. Cancer Chemother., 30, 73-80 (2003).
19. Japanese Gastric Cancer Association,: 〈http:// www.jgca.jp/PDF files/GL2004.PDF〉, Kanaharashuppann Co., Ltd., Tokyo, 2004, pp. 1-43.
20. Griffin A. M., Butow P. N., Coates A. S., Childs A. M., Ellis P. M., Dunn S. M., Tattersall M. H. N., Ann. Oncol., 7, 189-195 (1996).
21. Carelle N., Piotto E., Bellanger A., Germanaud J., Thuillier A., Khayat D., Cancer, 95, 155-163 (2002).
22. Standard Gamble (SG); A method for estimating the preference of a given choice under conditions of uncertainty. Given that a patient with a certain disease receives a treatment and "will die if the treatment fails" or "will lead a healthy life if the treatment is successful," this technique inquires "what probability of success is required for the selection of that treatment" and the responded probability is considered as the utility value for the disease or condition.
23. Time Trade-Off TTO); A method for estimating the preference of a given choice under conditions of certainty. It inquires "what number of years spent in a healthy condition is equivalent to 10 years spent with a certain disease or condition." The utility value is calculated by dividing the number of years in the response by 10 years.
24. Rating Scale (RS); A method that uses a linear analogue scale with 0 representing death 0 and 1 representing perfect health. Respondents indicate the position on the scale that corresponds to a certain disease or condition, and the value of the indicated site is considered as the utility value.
25. Sasaki T., Maeda Y., Kobayashi T., Okamoto R., Komuro Y., Takeda N., Jpn. J. Cancer Chemother., 27, 166-176 (2000).
26. Japanese Gastric Cancer Association,:〈http:// www.jgca.jp/PDF files/GL2IPPAN.pdf〉, Kanaharashuppann Co., Ltd., Tokyo, 2004, pp. 1-76.
27. Ohtsu A., Shimada Y., Shirao K., Boku N., Hyodo I., Saito H., Yamamichi N., Miyata Y., Ikeda N., Yamamoto S., Hukuda H., Yoshida S., J. Clin. Oncol., 21, 54-59(2003).
28. Koizumi W., Tanabe S., Saigenji K., Ohtsu A., Boku N., Nagashima F., Shirao K., Matsumura Y., Gotoh M., Br. J. Cancer, 89, 2207-2212 (2003).
29. Kaminishi M., J. Jpn. Surg. Soc., 104, 395-398 (2003).
30. Nishimura Y., Mitsutake M., Nakanishi S., Konishi T., Jpn. J. Cancer Chemother., 27, 1360-1368 (2000).
31. Desch C. E., Hillner B. E., Smith T. J., Retchin S. M., J. Clin. Oncol., 11, 777-782 (1993).
32. Launois R., Marty J. R., Henry B., Bonneterre J., Pharmacoeconomics, 10, 504-521 (1996).
33. Ortega A., Dranitsaris G., Sturgeon J., Sutherland H., Oza A., Gynecol. Oncol., 66, 454-463 (1997).
34. Nord E., Wisloff F., Hjorth M., Westin J., Pharmacoeconomics, 12, 89-103 (1997).
35. Koinuma N., Takeyoshi H., Nippon Rinsho, 61, 1030-1038 (2003).
36. Ikeda S., Kobayashi M., Geriatr. Med., 42, 600-606 (2004).
37. Koinuma N., Geriatr. Med., 42, 579-586 (2004).